LENZ Therapeutics (LENZ) Fundamental Analysis: Revenue, Earnings & Valuation

3.28 / 10

Netural

Fundamental rating is Neutral with a 3.28 score. Profit‑MV and Cash‑MV show modest strength, while Asset‑MV and Revenue‑MV lag. Inventory turnover and cost‑of‑sales ratios are solid, but gross margin quality is low. Overall fundamentals are fragile, urging guarded optimism.

Analysis Checks(6/10)

Revenue-MV

Value-2.65

Score1/3

Weight16.33%

1M Return5.44%

Inventory turnover ratio

Value47.57

Score3/3

Weight19.82%

1M Return6.65%

Gross profit margin (%)

Value100.00

Score1/3

Weight0.77%

1M Return0.36%

Profit-MV

Value0.41

Score2/3

Weight18.64%

1M Return6.36%

Income tax / Total profit (%)

Value-1.09

Score1/3

Weight0.46%

1M Return0.21%

Current assets turnover ratio

Value0.08

Score2/3

Weight4.28%

1M Return1.91%

Fixed assets turnover ratio

Value8.55

Score3/3

Weight3.95%

1M Return1.76%

Cost of sales ratio (%)

Value70.30

Score3/3

Weight9.85%

1M Return4.08%

Asset-MV

Value-0.48

Score0/3

Weight7.65%

1M Return2.73%

Cash-MV

Value-0.09

Score2/3

Weight18.26%

1M Return6.19%

Is LENZ undervalued or overvalued?

LENZ scores 3.28/10 on fundamentals and holds a Fair valuation at present. Backed by its -23.23% ROE, 0.00% net margin, -4.37 P/E ratio, 1.33 P/B ratio, and 85.26% earnings growth, these metrics solidify its Netural investment rating.